Cardiovascular Events
1
Pipeline Programs
3
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 2 programs with unclassified modality
Competitive Landscape
3 companies ranked by most advanced pipeline stage
AstraZenecaCAMBRIDGE, United Kingdom
1 programSecondary Prevention Treatment in Patients Who Have Suffered a Cardiovascular EventN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
AstraZenecaSecondary Prevention Treatment in Patients Who Have Suffered a Cardiovascular Event
Clinical Trials (1)
Total enrollment: 88 patients across 1 trials
NCT01395550AstraZenecaSecondary Prevention Treatment in Patients Who Have Suffered a Cardiovascular Event
Secondary Prevention Treatment in Patients Who Have Suffered a Cardiovascular Event
Start: Jan 2010Est. completion: Jul 201088 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.